Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04176419
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
- Conditions
- Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Oral Cavity CarcinomaRecurrent Hypopharyngeal CarcinomaRecurrent Nasal Cavity and Paranasal Sinus CarcinomaStage III Laryngeal Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVA Laryngeal Cancer AJCC v8Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8Recurrent Oral Cavity CarcinomaStage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 60
- Registration Number
- NCT04162873
- Locations
- 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients with CRS
- Conditions
- Interventions
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Lawson Health Research Institute
- Target Recruit Count
- 44
- Registration Number
- NCT04147013
- Locations
- 🇨🇦
St. Joseph's Healthcare London, London, Ontario, Canada
🇸🇦King Abdulaziz University Hospital, Jeddah, Saudi Arabia
Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2023-12-05
- Target Recruit Count
- 42
- Registration Number
- NCT04115098
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04093323
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
- Conditions
- HER2/Neu NegativeProgesterone Receptor NegativePrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Triple-Negative Breast CarcinomaAnatomic Stage IIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04081389
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 85
- Registration Number
- NCT04041050
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
🇺🇸City of Hope /ID# 239769, Duarte, California, United States
A Multimodal Analgesia Protocol Adapted for Ambulatory Surgery
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 100
- Registration Number
- NCT04015908
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
- Conditions
- Interventions
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Heron Therapeutics
- Target Recruit Count
- 116
- Registration Number
- NCT03974932
- Locations
- 🇺🇸
Endeavor Clinical Trials, LLC., San Antonio, Texas, United States
🇺🇸Helen Keller Hospital, Sheffield, Alabama, United States
🇺🇸Phoenix Clinical Research, LLC, Tamarac, Florida, United States
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT03949673
- Locations
- 🇵🇱
Regeneron Recruting SIte, Bialystok, Poland
🇬🇧Regeneron Research Site, Liverpool, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.